Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

DARE-19, 2021 NCT04350593

dapagliflozin (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

dapagliflozin for 30 days

Control treatment

placebo

Patients

COVID 19 hospitalized

Method

Remark

trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality according to a AZ press release